Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,799 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.
Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo BY, Meng Z, Bai Y, Chen X, Liu X, Xiao J, Ho GF, Mao Y, Wang X, Ying J, Li J, Zhong W, Zhou Y, Siegel AB, Hao C. Qin S, et al. Among authors: mao y. J Clin Oncol. 2023 Mar 1;41(7):1434-1443. doi: 10.1200/JCO.22.00620. Epub 2022 Dec 1. J Clin Oncol. 2023. PMID: 36455168 Free PMC article. Clinical Trial.
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Clinical Trial.
Operable squamous esophageal cancer: current results from the East.
Zhang DW, Cheng GY, Huang GJ, Zhang RG, Liu XY, Mao YS, Wang YG, Chen SJ, Zhang LZ, Wang LJ, et al. Zhang DW, et al. Among authors: mao ys. World J Surg. 1994 May-Jun;18(3):347-54. doi: 10.1007/BF00316813. World J Surg. 1994. PMID: 8091774
[Comparison of lung cancer surgery in China, 2005 vs. 2015].
Li N, Tan FW, Qiu B, Li JG, Zhao J, Gao YS, Wang DL, Mao YS, Xue Q, Mu JW, Gao SG, He J. Li N, et al. Among authors: mao ys. Zhonghua Zhong Liu Za Zhi. 2018 Apr 23;40(4):300-302. doi: 10.3760/cma.j.issn.0253-3766.2018.04.012. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29730919 Chinese.
[The value of the planned neoadjuvant radiotherapy or chemoradiotherapy for the non-radical resection of esophageal squamous cell carcinoma].
Ni WJ, Deng W, Xiao ZF, Zhou ZM, Wang X, Chen DF, Feng QF, Liang J, Lyu JM, Bi N, Deng L, Zhang T, Wang WQ, Xue Q, Gao SG, Mu JW, Mao YS, Wang DL, Zhao J, Gao YS, Huang JF, Tan FW, Zhao L, Lyu F, Zhang GC. Ni WJ, et al. Among authors: mao ys. Zhonghua Zhong Liu Za Zhi. 2019 Apr 23;41(4):295-302. doi: 10.3760/cma.j.issn.0253-3766.2019.04.010. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31014056 Chinese.
[Epidemiological characteristic and current status of surgical treatment for esophageal cancer by analysis of national registry database].
Mao YS, Gao SG, Wang Q, Shi XT, Li Y, Gao WW, Guan FS, Li XF, Han YT, Liu YY, Liu JF, Zhang K, Liu SY, Fu XN, Fang WT, Chen LQ, Wu QC, Xiao GM, Chen KN, Jiao GG, Zhang SJ, Mao WM, Rong TH, Fu JH, Tan LJ, Chen C, Xu SD, Guo SP, Yu ZT, Hu J, Hu ZD, Yang YK, Ding NN, Yang D, He J. Mao YS, et al. Among authors: mao wm. Zhonghua Zhong Liu Za Zhi. 2020 Mar 23;42(3):228-233. doi: 10.3760/cma.j.cn112152-20191112-00729. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32252202 Chinese.
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Shi Y, Lei K, Jia Y, Ni B, He Z, Bi M, Wang X, Shi J, Zhou M, Sun Q, Wang G, Chen D, Shu Y, Liu L, Guo Z, Liu Y, Yang J, Wang K, Xiao K, Wu L, Yi T, Sun D, Kang M, Ma T, Mao Y, Shi J, Tang T, Wang Y, Xing P, Lv D, Liao W, Luo Z, Wang B, Wu X, Zhu X, Han S, Guo Q, Liu R, Lu Z, Zhang J, Fang J, Hu C, Ji Y, Liu G, Lu H, Wu D, Zhang J, Zhu S, Liu Z, Qiu W, Ye F, Yu Y, Zhao Y, Zheng Q, Chen J, Pan Z, Zhang Y, Lian W, Jiang B, Qiu B, Zhang G, Zhang H, Chen Y, Chen Y, Duan H, Li M, Liu S, Ma L, Pan H, Yuan X, Yuan X, Zheng Y, Gao E, Zhao L, Wang S, Wu C. Shi Y, et al. Among authors: mao y. Cancer Commun (Lond). 2021 Sep;41(9):889-903. doi: 10.1002/cac2.12179. Epub 2021 Jun 29. Cancer Commun (Lond). 2021. PMID: 34184418 Free PMC article. Clinical Trial.
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.
Xiong A, Ren S, Liu H, Miao L, Wang L, Chen J, Li W, Li R, Wang X, Lu Z, Wang D, Wu X, Liu Z, Xing L, Mao Y, Liu C, Zeng A, Niu H, Du Y, Sun Y, Pan Y, Hu Y, Zhang X, Chen X, Ma Z, Li N, Zhang J, Zhao M, Li X, Ye F, Li M, Yu G, Zhang X, Min J, Han D, Li J, Zhou C. Xiong A, et al. Among authors: mao y. J Thorac Oncol. 2022 Oct;17(10):1216-1226. doi: 10.1016/j.jtho.2022.06.013. Epub 2022 Jul 5. J Thorac Oncol. 2022. PMID: 35798241 Free article. Clinical Trial.
[Hotspots and prospects of esophageal cancer research in China].
Mao YS, Gao SG, Li Y, Xue Q, Li F, Jin DH, Yi H, He J. Mao YS, et al. Zhonghua Wei Chang Wai Ke Za Zhi. 2023 Apr 25;26(4):307-311. doi: 10.3760/cma.j.cn441530-20221222-00535. Zhonghua Wei Chang Wai Ke Za Zhi. 2023. PMID: 37072305 Chinese.
9,799 results